Global AMR R&D Hub Cross-Domain Award
Team 13292: Godswill Imolele Anthony (Team lead, Helix Biogen Institute) and Richard Gamah Teye (Valley View University)
Background and summary
Antimicrobial resistance, or AMR, is a growing threat because infections are becoming harder to treat as microbes stop responding to existing medicines. Although large surveillance datasets contain valuable information on resistance patterns, many current outputs mainly describe past trends rather than showing where resistance is accelerating, spreading, or becoming harder to explain.
This proposed research, Argus, will use the Vivli AMR Register Atlas dataset to turn AMR surveillance data into practical early-warning intelligence. It will identify where resistance is rising fastest, which resistance genes may be spreading across species and regions, where genetic results do not match laboratory resistance patterns, and which AMR threats require the most urgent attention. The project will also measure uncertainty, helping decision-makers understand how confident they can be in each signal.
Expected impact
Improve patient outcomes: Argus can support earlier detection of emerging resistance, helping clinicians and laboratories make better-informed treatment decisions and reduce the risk of ineffective antibiotic use.
Strengthen stewardship: By identifying high-risk pathogen–antibiotic combinations, the research can help stewardship teams target antibiotics more appropriately and update guidance based on stronger evidence.
Inform public health practice: The project will produce maps, networks, heatmaps, and risk scores that make complex AMR patterns easier to interpret, supporting surveillance planning, outbreak preparedness, and regional prioritisation.
Strengthen health systems: By linking AMR threat signals with global research funding data, Argus can highlight areas where serious AMR risks are under-funded or under-prioritised, helping health systems and funders allocate resources more strategically.